

Phone: 800.511.5144 • Fax: 877.541.1503

CROHN'S DISEASE AND ULCERATIVE COLITIS REFERRAL FORM A-Q

PATIENT INFORMATION					
Patient Name:		DOB:	Sex: <input type="checkbox"/> M <input type="checkbox"/> F <input type="checkbox"/> Other:		Weight: <input type="checkbox"/> lbs. <input type="checkbox"/> kg.
SSN:	Phone:	Allergies:			
Address:		City:	State:	Zip:	
Emergency Contact:		Phone:	<input type="checkbox"/> Additional Information Attached		
PRESCRIBER INFORMATION					
Prescriber:		NPI:	DEA:	State Lic:	
Supervising Physician:		Practice Name:			
Address:		City:	State:	Zip:	
Phone:	Fax:	Key Office Contact:		Phone:	
DIAGNOSIS INFORMATION / MEDICAL ASSESSMENT					
Primary Diagnosis: (ICD-10 Code & Description) <input type="checkbox"/> K50.00 <input type="checkbox"/> K50.10 <input type="checkbox"/> K50.80 <input type="checkbox"/> K50.90 Crohn's Disease <input type="checkbox"/> K51.9 Ulcerative Colitis <input type="checkbox"/> Other: _____					
<ul style="list-style-type: none"> ▪ Has patient been treated <i>previously</i> for this condition? <input type="checkbox"/> Yes <input type="checkbox"/> No Is patient <i>currently</i> on therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No Please list medication(s) and treatment duration: _____ ▪ Will patient stop taking the above medication(s) before starting the new medication? <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, how long should patient wait before starting the new medication? _____ ▪ Other medications patient is currently taking including OTC medications with dosage and direction (or fax medication profile): _____ ▪ Has patient received a Quatiferon gold, Tspot or PPD (tuberculosis) Skin Test? <input type="checkbox"/> Yes <input type="checkbox"/> No Date: _____ Results: <input type="checkbox"/> Negative <input type="checkbox"/> Positive 					
INSURANCE INFORMATION					
<input type="checkbox"/> Please attach front and back of patient's insurance card (medical and prescription)					
COPAY CARD ENROLLMENT					
<input type="checkbox"/> Please check if enrolling in copay card		Copay ID: _____			
PRESCRIPTION INFORMATION					
<input type="checkbox"/> STC Standard Protocol will include the following: (1) dispensing ordered med/dose, (2) diluent to mix and/or dilute dose, (3) flushes to flush line and anakit med (epinephrine 0.3 mg IM / 0.15 mg IM (for pediatric patients) and diphenhydramine 50 mg/mL) and (4) premeds to take 30 mins before orally (Apap 325 mg, may repeat x1, and diphenhydramine 25 mg, may repeat x1).					
Cimzia® <input type="checkbox"/> 200 mg/mL Prefilled Syringe <input type="checkbox"/> 200 mg Vial *Prefilled Syringes will be dispensed if no preference indicated		<input type="checkbox"/> Enroll in Cimplicity™ Program			
*Note: Cimzia Vial should be prepared and administered by a health care professional. AcariaHealth will coordinate home care with Cimplicity™ Program.					
<input type="checkbox"/> Starter Dose: 400 mg SQ (2 inj. of 200 mg) initially at Week 0, repeat at Weeks 2 and 4		QTY: <u>1 starter kit (6 PFS)</u> Refills: <u>0</u>			
<input type="checkbox"/> Maintenance Dose: <input type="checkbox"/> 400 mg SQ every 4 weeks <input type="checkbox"/> 200 mg SQ every 2 weeks		QTY: <u>1 box (2 x 200 mg)</u> Refills: _____			
Entyvio® <input type="checkbox"/> 300 mg Vial <input type="checkbox"/> MD's Office Infusion <input type="checkbox"/> Home Infusion Supplies Required		QTY: <u>3 vials</u> Refills: <u>0</u>			
<input type="checkbox"/> Starter Dose: 300 mg IV at Week 0, Week 2, Week 6		QTY: <u>1 vial</u> Refills: _____			
<input type="checkbox"/> Maintenance Dose: 300 mg IV every 8 weeks					
Entyvio® <input type="checkbox"/> 108mg Pen <input type="checkbox"/> 108mg Syringe		QTY: <u>2 pens/syringes</u> Refills: _____			
<input type="checkbox"/> Maintenance Dose: 108 mg SQ once every 2 weeks (beginning after at least 2 IV infusions; administer in place of next scheduled IV dose and then every 2 weeks thereafter)					
Humira® CF <input type="checkbox"/> Starter Package 80 mg / 0.8 mL Pen NDC: 0074-0124-03 See Biosimilar form for alternatives		<input type="checkbox"/> Enroll in Humira Complete Program			
Starter Dose: <input type="checkbox"/> Two 80 mg SQ inj. Day 1, one 80 mg SQ inj. Day 15		QTY: <u>3 pens</u> Refills: <u>0</u>			
<input type="checkbox"/> One 80 mg SQ inj. Day 1, one 80 mg SQ inj. Day 2, one 80 mg SQ inj. Day 15		QTY: <u>3 pens</u> Refills: <u>0</u>			
Humira® CF <input type="checkbox"/> 40 mg/0.4 mL Pen NDC: 0074-0554-02 <input type="checkbox"/> 40 mg/0.4 mL Prefilled Syringe NDC: 0074-0243-02 See Biosimilar form for alternatives		QTY: <u>2</u> Refills: _____			
Maintenance Dose: <input type="checkbox"/> One 40 mg SQ inj. Day 29 & every other week thereafter		Refills: _____			
<input type="checkbox"/> Alternate Dose: _____		QTY: _____ Refills: _____			
Omvoh®		QTY: <u>1 vial (28ds)</u> Refills: <u>2</u>			
<input type="checkbox"/> Starter Dose: 300mg vials: 300mg IV at weeks 0, 4, and 8		QTY: <u>1 pen (28ds)</u> Refills: _____			
<input type="checkbox"/> Maintenance Dose: 100mg autoinjector: 200mg (2 injectors) at week 12, then every 4 weeks thereafter		QTY: _____ Refills: _____			
<input type="checkbox"/> Other: _____		QTY: _____ Refills: _____			

Physician's Signature: _____ DAW (Dispense as Written) **Date:** _____

Prescriber certifies that this referral form contains an original signature and is signed by the treating physician. NO STAMPED SIGNATURES WILL BE ACCEPTED. Where required by law, send prescription on official state prescription blank. In the event requested agent is not available through AcariaHealth, this prescription shall be forwarded to an eligible pharmacy.

IMPORTANT NOTICE: This message may contain privileged and confidential information and is intended only for the individual named. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please notify the sender immediately if you have received this document by mistake, then destroy this document. Please direct all verification or notification to AcariaHealth or any of its subsidiaries using the contact information provided on this coversheet.